398472-14-5Relevant academic research and scientific papers
Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19
Foti, Robert S.,Rock, Dan A.,Han, Xiaogang,Flowers, Robert A.,Wienkers, Larry C.,Wahlstrom, Jan L.
experimental part, p. 1205 - 1214 (2012/04/04)
A series of omeprazole-based analogues was synthesized and assessed for inhibitory activity against CYP2C19. The data was used to build a CYP2C19 inhibition pharmacophore model for the series. The model was employed to design additional analogues with inh
4-(Heteroarylaminomethyl)-N-(2-aminophenyl)-benzamides and their analogs as a novel class of histone deacetylase inhibitors
Frechette, Sylvie,Leit, Silvana,Woo, Soon Hyung,Lapointe, Guillaume,Jeannotte, Guillaume,Moradei, Oscar,Paquin, Isabelle,Bouchain, Giliane,Raeppel, Stephane,Gaudette, Frederic,Zhou, Nancy,Vaisburg, Arkadii,Fournel, Marielle,Yan, Pu Theresa,Trachy-Bourget, Marie-Claude,Kalita, Ann,Robert, Marie-France,Lu, Aihua,Rahil, Jubrail,Robert MacLeod,Besterman, Jeffrey M.,Li, Zuomei,Delorme, Daniel
, p. 1502 - 1506 (2008/09/19)
The synthesis and biological evaluation of a variety of 4-(heteroarylaminomethyl)-N-(2-aminophenyl)-benzamides and their analogs is described. Some of these compounds were shown to inhibit HDAC1 with IC50 values below the micromolar range, indu
Inhibitors of histone deacetylase
-
, (2008/06/13)
The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
